METHODS FOR IDENTIFYING THERAPEUTICAL TARGETS IN TUMORS AND FOR DETERMINING AND TARGETING ANGIOGENESIS AND HEMOSTASIS RELATED TO ANDENOCARCINOMAS OF THE LUNG

摘要

Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF/SF) are potent mitogens with proven angiogenic activities in human and animal disease models. These growth factors display little overlap in angiogenesis signaling cascades. The application reports angiogenesis in lung adenocarcinomas to be coordinated by hemostatic events. The invention relates to a method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, the use of novel targets for identifying, determining, and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung, and the use of the therapeutical targets identified for screening and determining means and/or drugs. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies. Furthermore the aim is the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, determining and treating angiogenesis and hemostasis related to adenocarcinomas, in particular of advanced stage tumors of the lung. The method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, comprising the steps of - isolating RNA (1) from the tissue of the tumor; - determining for the isolated RNA (1) a gene expression profile (2) of at least two genes, wherein at least one gene (3) is coding for a VEGF activity modulator and at least one gene (4) is coding for a hemostatic factor by screening the presence of mRNA coding for the factors to be screened and by determining the levels of expression of thereof; - determining the changes of expression of the at least two genes screened by the gene expression profile (2) in comparison with healthy tissue or with an early stage tumor; and - identifying the therapeutical target as a hemostatic factor, being upregulated or downregulated.